Drugs / BT524
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03444324 | Apr 2018 → Sep 2023 | coagulation protein disease | Biotest | Completed | Met primary |
| Phase 3 | NCT02065882 | Mar 2013 → May 2020 | congenital afibrinogenemia | Biotest | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT524 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02065882 ↗ |
| Action | Restore | “rapid supplementation of fibrinogen to restore physiological plasma levels” NCT03444324 ↗ |
| Modality | Protein / enzyme biologic | “a human fibrinogen concentrate (BT524)” PMID 41702298 ↗ Feb 2026 |
| Route | Intravenous | “following intravenous administration” NCT02065882 ↗ |